VivoSeq
Respiratory

Bronchopulmonary Dysplasia

37

Pipeline Programs↗

15

Active Trials↗

21

Companies Involved↗

Bronchopulmonary Dysplasia is a moderately active landscape with 37 programs across 21 companies. The most active players are Meridigen Biotech Co., Ltd., Validus Pharmaceuticals, Asklepion Pharmaceuticals, LLC. 8 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

27/100

Mech. Concentration

33/100

Completion Rate

67/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Meridigen Biotech Co., Ltd.

1 program

Phase 1V

Validus Pharmaceuticals

1 program

Phase 1A

Asklepion Pharmaceuticals, LLC

1 program

Phase 1EMD Serono logo

EMD Serono

1 program

Phase 1Sanofi logo

Sanofi

1 program

Phase 2S

Shanghai IxCell Biotechnology Co., LTD

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical4

Caffeine Citrate

Kaken Pharmaceutical

PNEUMOSTEM

Medipost Co Ltd.

Inhaled Beclomethasone Dipropionate Monohydrate

Mount Sinai Hospital, Canada

Stool Collect

Assistance Publique - Hôpitaux de Paris

Phase 18

Furosemide

Validus Pharmaceuticals

L-Citrulline

Asklepion Pharmaceuticals, LLC

Metformin

EMD Serono

AT-100

Airway Therapeutics, Inc.

Mesenchymal Stem Cell Therapy

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Phase 211

Sildenafil

Viatris Specialty LLC

Nitric Oxide

Mallinckrodt

Montelukast

Organon and Co

Immunoglobulin

Sanofi

Inhaled Budesonide

University of British Columbia

Phase 36

Methylprednisolone

Pfizer

Dexamethasone

Aspen Global Incorporated

Hydrocortisone

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Caffeine

Hikma Pharmaceuticals LLC

Inhaled Nitric Oxide

Lee's Pharmaceutical Limited

Approved8

Tobramycin

Viatris Specialty LLC

Azithromycin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Beclomethasone Dipropionate

Schering-Plough

Clarithromycin

AbbVie

Budesonide

Salix

Analysis

Modality Breakdown

76%

Small molecule

35 of 46 classified programs — the dominant modality here.

24%ALL OTHERSCell therapy1022%Peptide12%

Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 100% of 57 pipeline programs.

Analysis

Trial Status

56

clinical trials

Completed18 · 32%
Unknown status14 · 25%
Recruiting10 · 18%
Withdrawn6 · 11%
Terminated3 · 5%
Not yet recruiting3 · 5%
Other2 · 4%

Clinical Trials

Trial Activity

56 trials

Metformin for Premature Infants With Bronchopulmonary Dysplasia
Recruiting·MMedical College of Wisconsin·Phase 1·NCT07120971·40 enrolled
Use of Mesenchymal Stem Cells in Pre-term Patients With Bronchopulmonary Dysplasia.
Recruiting·FFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal·Phase 2·NCT06270199·75 enrolled
Mesenchymal Stem Cells for Prevention of Bronchopulmonary Dysplasia in Infants
Recruiting·MMeridigen Biotech Co., Ltd.·Phase 1·NCT03631420·9 enrolled
Efficacy and Safety of Zelpultide Alfa in Preterm Neonates at High Risk of Developing Bronchopulmonary Dysplasia (BPD)
Recruiting·AAirway Therapeutics, Inc.·Phase 2/3·NCT06897839·366 enrolled
IVIG Trial for the Treatment of Bronchopulmonary Dysplasia
Recruiting·IInternational Peace Maternity and Child Health Hospital·Phase 2·NCT06925360·20 enrolled
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
Recruiting·OOHB Neonatology Ltd.·Phase 2·NCT03253263·338 enrolled
Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stem Cell(MSC) Transplantation in the Treatment of Bronchopulmonary Dysplasia(BPD) in Premature Infants
Recruiting·TThe Children's Hospital of Zhejiang University School of Medicine·Phase 1/2·NCT06788470·10 enrolled
Lipid Infusions to Optimize Nutrition (LION) and Minimize Bronchopulmonary Dysplasia and Neurodevelopmental Impairment in Extremely Preterm Infants: A Randomized Comparative Effectiveness Trial
Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06915441·230 enrolled
Pilot Trial Comparing Transpyloric to Gastric Feeding in Very Preterm Infants With Bronchopulmonary Dysplasia
Recruiting·CChildren's Hospital of Philadelphia·Preclinical·NCT06534359·60 enrolled
A Randomized Controlled Crossover Trial of Postpyloric Versus Gastric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants
Recruiting·BBoston Children's Hospital·Preclinical·NCT05777512·50 enrolled
Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia
Active, not recruiting·OOttawa Hospital Research Institute·Phase 1·NCT04255147·9 enrolled
Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia
Active, not recruiting·SSamsung Medical Center·N/A·NCT01632475·9 enrolled
Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants
Not yet recruiting·OOttawa Hospital Research Institute·Phase 2·NCT07058025·168 enrolled
PremaBiom: Metatranscriptomics of the Respiratory Microbiome to Predict the Occurrence of Bronchopulmonary Dysplasia in Preterm Infants
Not yet recruiting·UUniversity Hospital, Caen·N/A·NCT07411261·270 enrolled
Early Prediction of Bronchopulmonary Dysplasia Using Clinical Data From the First Three Postnatal Weeks in Preterm Infants: A Retrospective Study With Large Language Models
Not yet recruiting·KKonya City Hospital·N/A·NCT07525167·108 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)